Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6916 AL 6930

Targeted hydrolysis of Beta-amyloid with engineered antibody fragment

Kasturirangan S, Sierks M.

Curr Alzheimer Res. 2010 May;7(3):214-22. doi: 10.2174/156720510791050876.

New therapeutic strategy for Parkinson's and Alzheimer's disease

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. doi: 10.2174/092986710791859324.

Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology

O'Brien JT, Burns A; BAP Dementia Consensus Group.

J Psychopharmacol. 2011 Aug;25(8):997-1019. doi: 10.1177/0269881110387547. Epub 2010 Nov 18.

[Development of gene therapy in major brain diseases]

Fan L, Jiang XG.

Yao Xue Xue Bao. 2010 Sep;45(9):1095-102.

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea

Sabbagh MN, Shill HA.

Curr Opin Investig Drugs. 2010 Jan;11(1):80-91.

Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?

de la Monte SM.

J Alzheimers Dis. 2024;101(s1):S317-S343. doi: 10.3233/JAD-240069.

Chiral nanomaterial-based approaches for diagnosis and treatment of protein-aggregated neurodiseases: current status and future opportunities

Pranav, Bajpai A, Dwivedi PK, Sivakumar S.

J Mater Chem B. 2024 Feb 21;12(8):1991-2005. doi: 10.1039/d3tb02381h.

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

Zhang T, Kim BM, Lee TH.

Transl Neurodegener. 2024 Jan 9;13(1):4. doi: 10.1186/s40035-023-00395-5.

Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease

Crook H, Edison P.

J Alzheimers Dis. 2024;101(s1):S357-S370. doi: 10.3233/JAD-240730.

Novel insights into the activating transcription factor 4 in Alzheimer's disease and associated aging-related diseases: Mechanisms and therapeutic implications

Zhang N, Nao J, Zhang S, Dong X.

Front Neuroendocrinol. 2024 Jul;74:101144. doi: 10.1016/j.yfrne.2024.101144. Epub 2024 May 24.

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Kee TR, Khan SA, Neidhart MB, Masters BM, Zhao VK, Kim YK, McGill Percy KC, Woo JA.

Exp Mol Med. 2024 Feb;56(1):129-141. doi: 10.1038/s12276-023-01144-4. Epub 2024 Jan 11.

The Use of Neurotrophic Factors as a Promising Strategy for the Treatment of Neurodegenerative Diseases (Review)

Fursa GA, Andretsova SS, Shishkina VS, Voronova AD, Karsuntseva EK, Chadin AV, Reshetov IV, Stepanova OV, Chekhonin VP.

Bull Exp Biol Med. 2024 Aug;177(4):517-527. doi: 10.1007/s10517-024-06218-5. Epub 2024 Sep 12.

Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation

Monteiro KLC, de Aquino TM, da Silva-Júnior EF.

CNS Neurol Disord Drug Targets. 2024;23(10):1234-1250. doi: 10.2174/0118715273273539231114095300.

Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy

Abujamai J, Satar R, Ansari SA.

CNS Neurol Disord Drug Targets. 2024;23(10):1251-1262. doi: 10.2174/0118715273297024240201055550.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias